Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Export

@article{citeulike:5045099, abstract = {In recent years, quantitative metabolomics has played increasingly important roles in pharmaceutical research and development. Metabolic profiling of biofluids and tissues can provide a panoramic view of abundance changes in endogenous metabolites to complement transcriptomics and proteomics in monitoring cellular responses to perturbations such as diseases and drug treatments. Precise identification and accurate quantification of metabolites facilitate downstream pathway and network analysis using software tools for the discovery of clinically accessible and minimally invasive biomarkers of drug efficacy and toxicity. Metabolite abundance profiles are also indicative of biochemical phenotypes, which can be used to identify novel quantitative trait loci in genome-wide association studies. This review summarizes recent experimental and computational efforts to improve the metabolomics technology as well as progress towards in-depth integration of metabolomics with other disparate 'omics datasets to build mechanistic models in the form of detailed and testable hypotheses.}, author = {Xu, E. Y. and Schaefer, W. H. and Xu, Q.}, citeulike-article-id = {5045099}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/19152212}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=19152212}, issn = {2040-3437}, journal = {Current opinion in drug discovery \& development}, keywords = {metabolomic, pharma}, month = {January}, number = {1}, pages = {40--52}, posted-at = {2009-07-03 13:09:54}, priority = {0}, title = {Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/19152212}, volume = {12}, year = {2009} }

TY - JOUR ID - citeulike:5045099 L3 - citeulike-article-id:5045099 N2 - In recent years, quantitative metabolomics has played increasingly important roles in pharmaceutical research and development. Metabolic profiling of biofluids and tissues can provide a panoramic view of abundance changes in endogenous metabolites to complement transcriptomics and proteomics in monitoring cellular responses to perturbations such as diseases and drug treatments. Precise identification and accurate quantification of metabolites facilitate downstream pathway and network analysis using software tools for the discovery of clinically accessible and minimally invasive biomarkers of drug efficacy and toxicity. Metabolite abundance profiles are also indicative of biochemical phenotypes, which can be used to identify novel quantitative trait loci in genome-wide association studies. This review summarizes recent experimental and computational efforts to improve the metabolomics technology as well as progress towards in-depth integration of metabolomics with other disparate 'omics datasets to build mechanistic models in the form of detailed and testable hypotheses. IS - 1 JF - Current opinion in drug discovery & development SN - 2040-3437 EP - 52 TI - Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. VL - 12 SP - 40 KW - metabolomic KW - pharma AU - Xu, EY AU - Schaefer, WH AU - Xu, Q PY - 2009/01// UR - http://view.ncbi.nlm.nih.gov/pubmed/19152212 ER -